MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/igc.0b013e31824b403d

Медицинская библиотека · International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2012

Does significant medical comorbidity negate the benefit of up-front cytoreduction in advanced ovarian cancer?

Ferriss James Stuart, Ring Kari, King Erin R, Courtney-Brooks Madeleine, Duska Linda R, Taylor Peyton T

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

The objective of the study was to determine if initial surgery (IS) or initial chemotherapy (IC) affects rates of optimal surgery and survival in a population with significant medical comorbidities.

METHODS

Data of all patients with stage III-IV ovarian, peritoneal, and fallopian tube cancers diagnosed from 1995 to 2008 were reviewed. Clinical and pathologic data were abstracted.

RESULTS

There were 551 cases for review: 255 (46.3%) received IS, and 296 (53.7%) received IC. Patients who received IC had higher stage (P < 0.001), higher-grade cancers (P < 0.001), higher mean CA-125 (P = 0.015), higher rates of diabetes (P = 0.006), hypertension (P = 0.008), and presurgical embolism (P < 0.022) and were older (P = 0.043). There was no difference with respect to body mass index, albumin, extent of surgery, or intensive care use. Rates of optimal cytoreduction were higher with IC compared with IS (72.7% vs 56.1%, P < 0.001). IS was associated with more blood loss (P = 0.005) and higher rates of postsurgical venous thrombosis (P < 0.001). Optimal cytoreduction predicted survival in both groups. Among optimal patients, IS improved median survival: progression-free survival of 14 months (IS) versus 12 months (IC), P = 0.004; overall survival of 58 months (IS) versus 34 months (IC), P = 0.002. Factors influencing this difference were receipt of IC and history of diabetes; both predictors of mortality: hazard ratios, 1.9 (95% confidence interval, 1.3-2.8; P < 0.001) and 1.8 (95% confidence interval, 1.02-3.1; P = 0.042), respectively.

CONCLUSIONS

The achievement of optimal cytoreduction continues to be a significant predictor of survival, regardless of treatment approach. Patients selected for IS and in whom optimal cytoreduction was achieved had improvements in both progression-free survival and overall survival. However, the differences could not be explained by surgical effort alone as diabetes was independently associated with mortality.

Для цитирования: Ferriss James Stuart, Ring Kari, King Erin R, Courtney-Brooks Madeleine, Duska Linda R, Taylor Peyton T. Does significant medical comorbidity negate the benefit of up-front cytoreduction in advanced ovarian cancer?. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2012. DOI: 10.1097/igc.0b013e31824b403d.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.